Spiriva Respimat Highlights Me-Too Risk Calculations: How Clean Does Safety Need To Be?
Executive Summary
Boehringer’s Spiriva Respimat review shows how changing devices can create a more complicated benefit-risk assessment than might be anticipated.
You may also be interested in...
Spiriva Respimat Label Notes Lack Of Superiority To Spiriva HandiHaler
Boehringer Ingelheim will launch its new COPD inhalation spray in January; advisory committee had voted 10-3 for approval with some expressing concerns about potential safety issues.
FDA Review Division Takes Steps To Get Clear Answer From Advisory Panel
Pulmonary-Allergy Drugs Advisory Committee meeting shows FDA is working to improve meeting conduct and outcomes, but it’s not a center-wide project.
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.